Healthcare AI: faster returns, a different test for clinical trust
BESSEMER VENTURE PARTNERS + BAIN & COMPANY · SEPTEMBER 30, 2026
A 2026 survey of 226 healthcare executives across 65 AI use cases reports that returns arrived sooner than expected: roughly 12 months rather than the 24 months buyers had planned for, with an average return of 3.5 times the cost. The strongest returns are concentrated in administrative work. Revenue cycle management leads at 4.0x; provider clinical use cases report 2.9x. Semi- or fully autonomous agents account for 67% of provider revenue-cycle solutions, compared with 4% in clinical work.
How to read it
These are executives' self-reported returns, not an independent audit or a clinical trial. The findings are useful for understanding what surveyed buyers say is working. They do not establish that every healthcare organization will see the same savings, or that a financial return proves better patient outcomes. Bessemer is a venture investor, and the report discusses some of its portfolio companies.
Dr. Mohan's take
A faster return in the back office is encouraging. It is not the same as earning trust in a clinical decision. A tool that helps move a claim through a queue and a tool that helps interpret a patient's findings have different jobs and different consequences when they are wrong. Clinical trust has to be earned: validation for the task, clear reasons for the recommendation, and accountable human judgment. In pathology, the result still has to make sense in the specimen and the patient's context. The question is not only whether AI can produce an answer faster. It is whether the person responsible for that answer can rely on it, recognize its limits, and know when to look again.
Sources
For education only. This page does not offer personal medical advice.